GlassScriptPhysician profile
Claire Hiles
NPI 1447544473
$917.68
in general payments reported to CMS, 2019-2025
19 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $111 · 2021: $162 · 2022: $109 · 2023: $80.89 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.00 · Food and Beverage: $80.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.00 |
| Food and Beverage | $80.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $203.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.83 | 2019-2022 | |
| Janssen Biotech, INC. | $99.00 | 2025 | Tecvayli, Talvey, Darzalex |
| Ipsen Biopharmaceuticals, INC | $78.69 | 2019-2021 | |
| Abbvie INC. | $65.21 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $61.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.65 | 2021-2022 | |
| Exelixis INC. | $46.95 | 2019 | |
| Seagen INC. | $36.18 | 2020-2023 | Tukysa |
| Celgene Corporation | $24.64 | 2020 | |
| Karyopharm Therapeutics INC. | $24.38 | 2023 | Xpovio |
| Tesaro, INC. | $19.76 | 2019 | |
| Aveo Pharmaceuticals, INC. | $19.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.78 | 2022 | |
| Clovis Oncology, INC. | $17.57 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.47 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.80 | 2019 | |
| Incyte Corporation | $12.69 | 2022 | |
| Amgen INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Hiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.